(Q45253372)

English

Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type

scientific article published in January 1989

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 December 2017

Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type (English)

1 reference

Europe PubMed Central

11 December 2017

1 reference

based on heuristic

inferred from title

author name string

E Kedar

1

1 reference

Europe PubMed Central

11 December 2017

R Ben-Aziz

2

1 reference

Europe PubMed Central

11 December 2017

E Epstein

3

1 reference

Europe PubMed Central

11 December 2017

B Leshem

4

1 reference

Europe PubMed Central

11 December 2017

publication date

1 January 1989

1 reference

Europe PubMed Central

11 December 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

11 December 2017

29

1 reference

Europe PubMed Central

11 December 2017

74-78

1 reference

Europe PubMed Central

11 December 2017

1

1 reference

Europe PubMed Central

11 December 2017

https://scigraph.springernature.com/pub.10.1007/bf00199920

0 references

Immunotherapy of cancer using interleukin 2: current status and future prospects

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy in combination with chemotherapy for cancer treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Murine Antitumor Immune Response and Its Therapeutic Manipulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Experimental and clinical results

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current understanding of the lymphokine-activated killer cell phenomenon

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/2785003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00199920

1 reference

Europe PubMed Central

11 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45253372&oldid=2071399386"